10-Q 2026-07-30 ↗ compared with the reference 10-K 10-K 2026-02-12 ↗
Technical events and factor profile →
Dexcom adds risks of losing market share in key markets and expands its risk disclosure on regulatory scrutiny.
| After the 10-Q | 1 session | 5 sessions | 20 sessions |
|---|---|---|---|
| DXCM | -0.8% | +10.0% | +18.4% |
| Nasdaq-100 (QQQ) | +3.3% | +8.4% | +7.5% |
| Difference | -4.1% | +1.6% | +10.9% |
From the close before the filing. Historical data, not a prediction.
This filing includes no relevant new risks: the changes are rewording.
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.3B | $1.2B | $1.2B |
| YoY growth | +13.1% | +15.0% | +13.1% | +21.6% | +15.2% |
| Gross margin | 63.4% | 62.9% | 62.9% | 60.5% | 59.5% |
| Operating margin | 24.3% | 21.4% | 25.6% | 20.1% | 18.4% |
| Net income | $249M | $200M | $267M | $284M | $180M |
| Diluted EPS | 0.64 | 0.51 | 0.67 | 0.70 | 0.45 |
XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.
0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors
Similar than in the previous 10-Q (2026-04-30: +12, -1 points)
10-Q of 2026-07-30 · 25.0% positive sentences, 13.8% negative · 152 sentences analysed
Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.
| Bridgewater Associates · Ray Dalio
held since Q3 2023 or earlier |
0.1% | $27.0M | +187% |
Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.
All material events for DXCM →
| 2026-09-28 | Stern Sadie · Officer | Sell (10b5-1 plan) | $221K | SEC ↗ |
| 2026-09-15 | AUGUSTINOS NICHOLAS · Director | Sell (10b5-1 plan) | $550K | SEC ↗ |
| 2026-09-15 | Brown Michael Jon · Officer | Sell (10b5-1 plan) | $143K | SEC ↗ |
| 2026-09-14 | AUGUSTINOS NICHOLAS · Director | Sell (10b5-1 plan) | $130K | SEC ↗ |
| 2026-09-10 | Sylvain Jereme M · Officer | Sell (10b5-1 plan) | $303K | SEC ↗ |
Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.